Objectives
Transcatheter aortic valve implantation (TAVI) has become an important interventional option for severe aortic stenosis in patients who are deemed inoperable or at high surgical risk. In this study, we aimed to present our single tertiary center experience with the Medtronic CoreValve prosthesis (CVP).
Methods
A total of 108 patients (63 % female, mean age: 76±9.0 years) who underwent transfemoral CVP implantation in between February 2013 and December 2015 at our clinic were enrolled. All pre- and post-procedural data was collected from the hospital registry and procedural notes. Statistical analysis was performed using SPSS.
Methods
A total of 108 patients (63 % female, mean age: 76±9.0 years) who underwent transfemoral CVP implantation in between February 2013 and December 2015 at our clinic were enrolled. All pre- and post-procedural data was collected from the hospital registry and procedural notes. Statistical analysis was performed using SPSS.